Preview Mode Links will not work in preview mode

Mar 20, 2017

1) Pure autonomic failure: Predictors of conversion to clinical CNS involvement2) What's Trending: ocrelizumab in multiple sclerosis 3) Topic of the Month: neuro-oncologyThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the March 21, 2017 issue of Neurology. In the first segment, Dr. Jeff Ratliff interviews Dr. Wolfgang Singer about his paper on pure autonomic failure. For our “What's Trending” feature of the week, Dr. Mark Keegan talks with Dr. Stephen Hauser about his paper on ocrelizumab in multiple sclerosis. In the next part of the podcast Dr. Kait Nevel focuses her interview with Dr. Lisa DeAngelis on metastatic disease. Disclosures can be found at Singer serves as Associate Editor for Clinical Autonomic Research; serves on the Autonomic Neuroscience: Basic and Clinical editorial board; holds a patent for use of 3,4 diaminopyridine in the treatment of orthostatic hypotension and postural tachycardia syndrome; received research support from NH, FDA, Cure MSA Foundation, Dysautonomia International, and American Dysautonomia Institute. Dr. Keegan serves on editorial boards for eMedicine (Chief Editor 2009-2015) and Multiple Sclerosis and Related Disorders; receives publishing royalties from Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases: Case-Based Learning Cambridge University Press 2016; consulted for Novartis, Bristol Meyers Squibb, and Bionest Partners; and received research support from Terumo Corporation and BCT International Ltd.Dr. Hauser serves on scientific advisory boards for Bionure, Annexon, Symbiotix, Neurona, and Molecular Telescope; receives publishing royalties from Harrison's Principles of Intervnal Medicine (McGraw Hill 1994); holds stock options in Bionure, Annexon, Symbtiotix, all of which were transferred to University of California – San Francisco; and received funding from NIH, National Multiple Sclerosis Society, and the Conrad Hilton Foundation.Dr. DeAngelis serves on scientific advisory board for Celgene and CarThera; serves on editorial boards for Neurology, Neuro-Oncology, Journal of Neuro-oncology, and Neuro-Oncology Practice; receives publishing royalties from The Neurologic Complications of Cancer (Oxford University Press 2008); and receives research support from NIH.All other participants report no disclosures.